

Female sex is linked to a stronger association between sTREM2 and CSF p-tau in Alzheimer's disease

Davina Biel ¹✉, Marc Suárez-Calvet ^{2,3,4,5}, Anna Dewenter¹, Anna Steward ¹, Sebastian N Roemer ^{1,6}, Amir Dehsarvi ¹, Zeyu Zhu¹, Julia Pescoller¹, Lukas Frontzkowski^{1,7}, Annika Kreuzer⁷, Christian Haass ^{8,9,10}, Michael Schöll ¹¹, Matthias Brendel^{7,8,9,12} & Nicolai Franzmeier ^{1,9,11,12}

Abstract

In Alzheimer's disease (AD), A β triggers p-tau secretion, which drives tau aggregation. Therefore, it is critical to characterize modulators of A β -related p-tau increases which may alter AD trajectories. Here, we assessed whether factors known to alter tau levels in AD modulate the association between fibrillar A β and secreted p-tau₁₈₁ determined in the cerebrospinal fluid (CSF). To assess potentially modulating effects of female sex, younger age, and ApoE4, we included 322 ADNI participants with cross-sectional/longitudinal p-tau₁₈₁. To determine effects of microglial activation on p-tau₁₈₁, we included 454 subjects with cross-sectional CSF sTREM2. Running ANCOVAs for nominal and linear regressions for metric variables, we found that women had higher A β -related p-tau₁₈₁ levels. Higher sTREM2 was associated with elevated p-tau₁₈₁, with stronger associations in women. Similarly, ApoE4 was related to higher p-tau₁₈₁ levels and faster p-tau₁₈₁ increases, with stronger effects in female ApoE4 carriers. Our results show that sex alone modulates the A β to p-tau axis, where women show higher A β -dependent p-tau secretion, potentially driven by elevated sTREM2-related microglial activation and stronger effects of ApoE4 carriership in women.

Keywords Alzheimer's Disease; Microglia; sTREM2; p-tau; Sex Differences

Subject Category Neuroscience

<https://doi.org/10.1038/s44321-024-00190-3>

Received 2 August 2024; Revised 18 December 2024;

Accepted 18 December 2024

Published online: 10 January 2025

Introduction

Beta-amyloid (A β) and tau are the hallmark pathologies of Alzheimer's disease (AD), ensuing neurodegeneration and cognitive decline (Jack et al, 2018). Previously it was shown that A β -oligomers trigger the neuronal secretion of soluble phosphorylated tau (p-tau) (Jin et al, 2011), which in turn drives the aggregation and trans-synaptic spread of neurofibrillary tau tangle pathology (Pichet Binette et al, 2022). These findings indicate that A β -related p-tau increases are critical for the subsequent development of tau aggregates. While the sequence of the amyloid cascade is well-established (Glenner and Wong, 1984; Hardy and Selkoe, 2002; Selkoe and Hardy, 2016), the progression rate of A β -initiated tau accumulation differs significantly between patients, causing heterogeneous disease trajectories and dynamics across patients (Dujardin et al, 2020; Komarova and Thalhauser, 2011; Landau et al, 2022). The aim of the present study is therefore to determine modulating factors of the A β to p-tau axis, which can help identify factors that accelerate or attenuate tau progression and determine targets to attenuate p-tau secretion and subsequent tau aggregation. To this end, we specifically focused on factors that have been previously associated with an increased risk of tau pathology in AD, which are female sex, microglial activation, younger age, and ApoE4, which is the main genetic risk factor for AD.

Accumulating evidence indicates that women are more severely affected by AD than men (Buckley et al, 2019b; Fisher et al, 2018; Laws et al, 2018; Levine et al, 2021; Mosconi et al, 2017; Nebel et al, 2018; Vest and Pike, 2013), accounting for two-thirds of AD dementia cases in the US (Alzheimer's, 2014). Previous work revealed that women show increased levels of CSF total tau and p-tau (Hohman et al, 2018), tau deposition (Buckley et al, 2019b), and a faster tau accumulation rate compared to men (Smith et al, 2020). Recently it was found that faster tau accumulation in women was facilitated by a stronger association between A β fibrils and

¹Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany. ²BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain. ³IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. ⁴Servei de Neurologia, Hospital del Mar, Barcelona, Spain. ⁵Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain. ⁶Department of Neurology, University Hospital, LMU Munich, Munich, Germany. ⁷Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany. ⁸German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. ⁹Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. ¹⁰Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, Germany. ¹¹University of Gothenburg, The Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Mölndal and Gothenburg, Sweden. ¹²These authors contributed equally: Matthias Brendel, Nicolai Franzmeier. ✉E-mail: Davina.Biel@med.uni-muenchen.de

soluble p-tau in women compared to men, suggesting early A β -dependent tau secretion as a critical turnover point for the observed sex differences in AD (Wang et al, 2024). Although the driving mechanisms behind these findings are not fully clear, differences in sex hormones (Sundermann et al, 2020) and inflammatory processes (Casaletto et al, 2022) are assumed to play an underlying role in the manifestation of sex differences in AD. In this context, analysis of post-mortem brain tissue of older adults show that microglial activation mediated the association between A β plaque pathology and neurofibrillary tau tangles in women but not in men (Casaletto et al, 2022). An association between microglial activation and the accumulation and spread of tau in AD has been previously shown in vitro (Brelstaff et al, 2021; Maphis et al, 2015) and in vivo (Pascoal et al, 2021; Vogels et al, 2019), thus microglial activation may play an early key role in the amyloid cascade (Pascoal et al, 2021). From a mechanistic point of view, microglia are the brains innate immune cells, which react to hazardous stimuli with the release of pro-inflammatory cytokines. Once the hazard stimulus has been eliminated, microglia return to their original homeostatic resting state. However, in chronic inflammation, microglia lose their capability to return back to their homeostatic state, resulting in neurotoxicity and tissue damage (Bivona et al, 2023). The Triggering Receptor Expressed on Myeloid Cell 2 (TREM2) has been associated with a shift of microglia from homeostatic to disease associated states (Keren-Shaul et al, 2017; Krasemann et al, 2017), parallels PET-assessed microglial activation (Brendel et al, 2017), and is thus a well-established proxy for microglial activation (Ewers et al, 2020; Ewers et al, 2019; Franzmeier et al, 2020). We and others showed recently that increased CSF sTREM2 levels are associated with higher levels of p-tau in early phases of sporadic AD (Suarez-Calvet et al, 2019), and mediate A β -related p-tau increases in earliest A β fibrillization (Biel et al, 2023). Thus, microglial activation might have a pivotal role in the early pathogenesis of AD, with different effects in men and women.

A further potential modulator of the A β to p-tau axis might relate to the patient's age. In addition to the effects of sex and sTREM2-related microglial activation, studies show that younger age at symptom onset is associated with a worsened prognosis and faster tau accumulation in sporadic AD (Frontzkowski et al, 2022; Koedam et al, 2008; van der Vlies et al, 2009). However, it remains unclear, whether younger age modulates the A β to p-tau axis towards a faster p-tau increase, which would support the view of a more aggressive form of AD when patients enter the amyloid cascade at younger age (Koedam et al, 2008; Touroutoglou et al, 2023).

Finally, genetic predispositions might play a critical role for early tau pathology. The ϵ 4 allele of the ApoE-encoding apolipoprotein (ApoE4) is the main genetic risk factor for sporadic AD, and carriership of the ApoE4 risk allele has been linked to an oversupply of cholesterol, ensuing accelerated A β production (Lee et al, 2021), neuroinflammation (Ophir et al, 2005), impaired myelination (Blanchard et al, 2022), and tau-mediated neurodegeneration (Shi et al, 2017). Further, ApoE4 carriership is associated with lower levels of testosterone (Hogervorst et al, 2002), a sex hormone which is mostly expressed in males and associated with anti-inflammatory processes (Bianchi, 2019; Ota et al, 2012) and cholesterol clearance (Kilby et al, 2021). Previously, we showed that ApoE4 drives A β -related tau

accumulation at lower levels of A β pathology, suggesting that in ApoE4 carriers, tau accumulation starts earlier than in ApoE4 non-carriers (Steward et al, 2023). In addition, several studies indicate that female ApoE4 carriers show enhanced levels of soluble CSF total tau (Altmann et al, 2014; Babapour Mofrad et al, 2020; Buckley et al, 2019a; Damoiseaux et al, 2012; Hohman et al, 2018) and p-tau (Babapour Mofrad et al, 2020; Hohman et al, 2018) compared to their male counterparts, hence, the association between ApoE4 carriership and A β -dependent tau might be further modulated by sex.

Together, female sex, microglial activation, younger age, and ApoE4-related genetic predisposition for AD have been previously associated with increased tau burden. The main aims of the present study were therefore to test, (i) whether sex, sTREM2-related microglial activation, younger age or ApoE4 modulate the A β to p-tau axis, and (ii) whether the effects of sTREM2, younger age or ApoE4 are stronger in women than in men.

Results

Sample characteristics

To assess whether sex, age, or ApoE4 modulates the A β to p-tau axis, we included 144 CN A β - controls, as well as 178 participants across the AD spectrum as defined by A β + status [CN/MCI/Demented=48/115/15] with cross-sectional and longitudinal CSF p-tau₁₈₁ data. The average follow-up time from baseline for p-tau₁₈₁ was 3.54 ± 1.97 years. As expected, the A β + group showed higher baseline levels of p-tau₁₈₁, higher p-tau₁₈₁ change rates and had a higher likelihood of ApoE4 positivity. For the assessment of CSF sTREM2 as a potential modulator of the A β to p-tau₁₈₁ axis, only cross-sectional data were available. 160 CN A β - and 294 A β + [CN/MCI/Demented=41/160/93] participants with sTREM2 and cross-sectional p-tau₁₈₁ data were included. As for the longitudinal sample, the A β + group showed higher p-tau₁₈₁ levels. For detailed descriptive statistics, see Table 1.

Higher sTREM2 levels and ApoE4 as risk factors for increased p-tau₁₈₁ levels

We tested first whether sex, CSF sTREM2, age, or ApoE4 are associated with increased cross-sectional or longitudinal CSF p-tau₁₈₁ levels. To that end, we calculated main effects using ANCOVAs for nominal potential modulators (i.e., sex, ApoE4) and linear regression for metric potential modulators (i.e., sTREM2, age). We found that higher sTREM2 was related to higher p-tau₁₈₁ levels ($T = 10.098$, $p < 0.001$, $p_{FDR} < 0.001$, partial $R^2 = 0.186$; Fig. 1C), and that ApoE4 was related to higher p-tau₁₈₁ levels ($F = 45.398$, $p < 0.001$, $p_{FDR} < 0.001$, $\eta^2 = 0.13$; Fig. 1F) and faster p-tau₁₈₁ increases ($F = 8.915$, $p = 0.003$, $p_{FDR} = 0.009$, $\eta^2 = 0.03$; Fig. 1G). Neither sex nor age were linked to constitutively higher p-tau₁₈₁ levels (sex: $F = 2.845$, $p = 0.093$, Fig. 1A; age: $T = 1.047$, $p = 0.296$, Fig. 1D) or faster p-tau₁₈₁ increases (sex: $F = 1.611$, $p = 0.205$, Fig. 1B; age: $T = 0.938$, $p = 0.349$, Fig. 1E). The results are summarized in Table 2. In line with previous work, we found that sTREM2-related microglial activation and ApoE4 positivity are related to higher levels in p-tau₁₈₁, suggesting a critical role of both factors in the onset of tau pathology.

Table 1. Demographics.

	Controls (Aβ [−])	AD spectrum (Aβ ⁺)	p-values
Modulators sex, age, education, ApoE4			
N	144	178	
Clinical status (CN/MCI/Dem)	144/0/0	48/115/15	<0.001
Sex (male/female)	71/73	85/93	0.869
Age in years	72.72 (6.57)	73.35 (6.57)	0.394
Years of education	16.97 (2.38)	16.07 (2.57)	0.001
CSF Aβ ₁₋₄₂ (pg/ml)	1517.16 (552.09)	760.11 (315.95)	<0.001
CSF p-tau ₁₈₁ (pg/ml)	19.46 (7.22)	33.94 (15.17)	<0.001
Amyloid-PET (centiloid)	−7.87 (11.80)	76.73 (35.77)	<0.001
ApoE4 status (non-carrier/carrier)	119/25	66/112	<0.001
Follow-up CSF p-tau ₁₈₁ (mean years)	3.72 (2.18)	3.40 (1.77)	0.145
CSF p-tau ₁₈₁ change rate	0.38 (0.34)	0.75 (0.62)	<0.001
Modulator sTREM2			
N	160	294	
Clinical status (CN/MCI/Dem)	160/0/0	41/160/93	<0.001
Sex (male/female)	79/81	165/129	0.201
Age in years	72.60 (6.41)	73.81 (7.32)	0.079
Years of education	16.91 (2.39)	15.85 (2.71)	<0.001
CSF Aβ ₁₋₄₂ (pg/ml)	1411.73 (396.05)	631.87 (174.24)	<0.001
CSF p-tau ₁₈₁ (pg/ml)	19.73 (7.46)	34.52 (15.17)	<0.001
CSF sTREM2 (pg/ml)	3940.74 (1992.21)	3966.61 (2210.14)	0.902
Amyloid-PET (centiloid)	−7.22 (12.08)	82.55 (33.31)	<0.001

Values are presented as mean (SD); p-values were derived from ANOVAs for continuous measures and from Chi-squared tests for categorical measures.
Aβ status (−/+) was defined on global amyloid-PET SUVRs.
CN cognitively normal, MCI mild cognitive impairment, Dem demented.

Female sex is associated with stronger amyloid-dependent p-tau₁₈₁ secretion

Next, we determined whether sex, CSF sTREM2, age, or ApoE4 specifically modulate the Aβ to p-tau axis and increase Aβ-dependent p-tau₁₈₁ secretion, which may translate into faster downstream tau aggregation and spread. Here, we found that solely sex modulates the association between centiloid and p-tau₁₈₁, where women compared to men showed higher Aβ-related p-tau₁₈₁ levels (T = 2.746, p = 0.006, p_{FDR} = 0.026; partial R² = 0.023; Fig. 2A) and faster p-tau₁₈₁ increases (T = 2.169, p = 0.031; partial R² = 0.015; Fig. 2B) which reached trend level significance after FDR correction (p_{FDR} = 0.092). Neither sTREM2, age, or ApoE4 modulated Aβ-related p-tau₁₈₁ levels (sTREM2: T = 0.422, p = 0.673, Fig. 2C; age: T = −0.240, p = 0.810, Fig. 2D; ApoE4: T = −0.513, p = 0.608, Fig. 2F) or faster p-tau₁₈₁ increases (age: T = 0.516, p = 0.606, Fig. 2E; ApoE4: T = −1.409, p = 0.160, Fig. 2G). The results are summarized in Table 2. The results indicate that sex

is associated with modulation of the Aβ to p-tau axis, suggesting a stronger association between Aβ-dependent p-tau₁₈₁ secretion and eventually faster tau aggregation in women compared to men. In contrast, our analysis did not provide statistical evidence that sTREM2, age, or ApoE4 significantly modulate the Aβ to p-tau axis.


sTREM2 promotes higher amyloid-dependent p-tau₁₈₁ levels in women compared to men

Next, we aimed to test whether female sex is associated with a higher vulnerability for detrimental effects of potential modulators on CSF p-tau₁₈₁ levels, and specifically, the Aβ to p-tau axis. To that end, we determined interaction effects of each potential modulator (i.e., CSF sTREM2, age, ApoE4) and sex on cross-sectional or longitudinal p-tau₁₈₁ levels. The analysis revealed a significant effect of sex on the association between sTREM2 and p-tau₁₈₁, with women showing a stronger association between sTREM2 and p-tau₁₈₁ levels compared to men (T = 2.177, p = 0.030, p_{FDR} = 0.045; partial R² = 0.011; Fig. 3A). Post hoc analyses calculating separate linear regression analyses for men and women further revealed higher partial R² values in women (T = 8.286, p < 0.001, partial R² = 0.253) vs. men (T = 5.978, p < 0.001, partial R² = 0.132), supporting a stronger association between sTREM2 and p-tau₁₈₁ in women than in men. In addition, we detected a significant interaction between ApoE4 carriership and sex on p-tau₁₈₁, where female ApoE4 carriers compared to male ApoE4 carriers showed higher levels of p-tau₁₈₁ (T = 2.185, p = 0.030, p_{FDR} = 0.045; partial R² = 0.015; Fig. 3B) but no faster p-tau₁₈₁ increases (T = 1.119, p = 0.264). There was no significant effect of sex on the association between age and p-tau₁₈₁ levels (T = −1.005, p = 0.315) or p-tau₁₈₁ increases (T = −0.735, p = 0.463). The findings show that the associations between sTREM2-related microglial activation as well as ApoE4 status on p-tau₁₈₁ levels are stronger in women than in men.

As a last step, we assessed whether sex further modulates the Aβ to p-tau axis by interacting with potential modulators. Thus, we assessed the association between centiloid, each potential modulator (i.e., sTREM2, age, ApoE4), and sex on cross-sectional or longitudinal p-tau₁₈₁ levels. We detected a significant centiloid x sTREM2 x sex interaction on cross-sectional p-tau₁₈₁ (T = 2.316, p = 0.021; partial R² = 0.012; Fig. 3C), where higher sTREM2 levels in women were associated with higher p-tau₁₈₁ levels at a given level of Aβ. However, the analysis only reached borderline significance after FDR correction (p_{FDR} = 0.063). Age or ApoE4 did not show interaction effects with sex on Aβ-dependent p-tau₁₈₁ levels (age: T = 0.009, p = 0.993; ApoE4: T = 0.362, p = 0.718) or p-tau₁₈₁ increases (age: T = 0.357, p = 0.721; ApoE4: T = 0.476, p = 0.634). The results are summarized in Table 3. These findings indicate that women show a trend for a different effect of sTREM2-related microglial activation on the Aβ to p-tau axis than men, which might result in higher tau burden and worsened disease progression in women.

Discussion

In the present study, we systematically assessed modulating factors of the Aβ to p-tau axis, i.e., a potentially critical driver of tau



fibrillization in AD (Pichet Binette et al, 2022), to better understand heterogeneity in pathophysiological disease progression. Specifically, we assessed whether sex, microglial activation (i.e., sTREM2), age or genetic predisposition for AD (i.e., ApoE4) are associated with higher levels in p-tau₁₈₁, and specifically, modulate the Aβ to

p-tau axis. Since women are at increased risk of AD, we further tested whether effects of any potential Aβ to p-tau modulator are stronger in women than in men. First, we show that sTREM2 and ApoE4 are associated with higher p-tau₁₈₁ levels and that the effects were even more pronounced in women than in men. Second, we

Figure 1. Main effects of potential modulators and CSF p-tau₁₈₁ across Aβ[−] cognitively normal plus Aβ⁺ ranging from cognitively normal to AD demented (longitudinal sample: N = 322; sTREM2 sample: N = 454).

Significant main effects were found between CSF sTREM2 and cross-sectional CSF p-tau₁₈₁ (C, $p < 2e-16$) and between ApoE4 carriership (non-carriers: $n = 185$; carriers: $n = 137$) and cross-sectional (F, $p = 7.69e-11$) and longitudinal (G) p-tau₁₈₁ levels. Sex (male: $n = 156$; female: $n = 166$) (A, B) and age (D, E) were not associated with higher p-tau₁₈₁ levels or faster p-tau₁₈₁ increases. F and p-values were derived for nominal variables (A, B, F, G) from ANCOVAs, and standardized beta-estimates (β) and p-values were derived for metric variables (C, D, E) from linear regressions. (A) and (B) were controlled for age, education, clinical status, and amyloid-PET (in centiloid); (C), (F), and (G) were controlled for sex, age, education, clinical status, and centiloid; (D) and (E) were controlled for sex, education, clinical status, and centiloid. The center line of each boxplot (A, B, F, G) indicates the median (50th percentile), the bounds of the box show the interquartile range (25–75th percentiles), and the whiskers extend to 1.5 times the interquartile range from the edges of the box. * = $p_{FDR} < 0.05$.

Table 2. Main and interaction effects of potential modulators on cross-sectional and longitudinal CSF p-tau₁₈₁ levels.

Model	Covariates	Cross-sectional			Longitudinal		
Main effects modulators on p-tau							
ANCOVA							
		F	p		F	p	
CSF p-tau ₁₈₁ ~ sex	Age, education, clinical status, CL	2.845	0.093		1.611	0.205	
CSF p-tau ₁₈₁ ~ ApoE4	Sex, age, education, clinical status, CL	45.398	<0.001*		8.915	0.003*	
Linear regression							
		β	T	p	β	T	p
CSF p-tau ₁₈₁ ~ sTREM2	Sex, age, education, clinical status, CL	0.371	10.098	<0.001*			
CSF p-tau ₁₈₁ ~ age	Sex, education, clinical status, CL	0.051	1.047	0.296	0.051	0.938	0.349
Interactions CL x modulators on p-tau		β	T	p	β	T	p
CSF p-tau ₁₈₁ ~ CL*sex	Age, education, clinical status	0.206	2.746	0.006*	0.182	2.169	0.031#
CSF p-tau ₁₈₁ ~ CL*CSF sTREM2	Sex, age, education, clinical status	0.037	0.422	0.673			
CSF p-tau ₁₈₁ ~ CL*age	Sex, education, clinical status	−0.137	−0.240	0.810	0.327	0.516	0.606
CSF p-tau ₁₈₁ ~ CL*ApoE4	Sex, age, education, clinical status	−0.045	−0.513	0.608	−0.138	−1.409	0.160

Main effects of sex and ApoE4 on p-tau₁₈₁ were calculated using ANCOVAs and main effects of CSF sTREM2 and age on p-tau₁₈₁ using linear regressions.

Interaction effects between modulators and the association between amyloid-PET (in centiloid; CL) and p-tau₁₈₁ levels were calculated using linear regressions.

* = $p_{FDR} < 0.05$; # = $p_{FDR} < 0.1$.

show that solely sex modulates Aβ-dependent p-tau₁₈₁ levels, with stronger Aβ-dependent p-tau₁₈₁ secretion in women compared to men. Finally, we observed a trend for sex differences for the association between sTREM2 and Aβ-dependent p-tau₁₈₁ levels, again, with higher p-tau₁₈₁ levels in women than in men. Together, our results underline sex-specific dynamics in AD disease pathways with more severe consequences for higher p-tau₁₈₁ levels in women. The findings are critical for patient stratifications in clinical trials, especially for drugs targeting microglial activation as a disease modifying approach.

Previously, higher levels of soluble (Hohman et al, 2018; Tsiknia et al, 2022) and aggregated tau (Buckley et al, 2019b; Shokouhi et al, 2020) were found in women compared to men. Congruently, we found that women showed stronger Aβ-related p-tau₁₈₁ secretion and trend to have faster Aβ-related p-tau₁₈₁ increases than men ($p_{FDR} = 0.092$), with sex being the only tested factor that modulated the Aβ to p-tau axis. However, future studies are needed to further investigate the effect of sex on Aβ-related longitudinal p-tau propagation. Besides a main effect of sTREM2-related microglial activation on p-tau₁₈₁ levels, we further revealed a stronger association between sTREM2 and p-tau₁₈₁ in women than in men. When testing whether this observation could be

applied to the Aβ to p-tau axis, we found a 3-way interaction of Aβ, sTREM2, and sex on p-tau₁₈₁, showing that in women, higher levels of sTREM2 were linked to a stronger Aβ-dependent p-tau₁₈₁ response. However, when applying FDR correction, the result only reached borderline significance ($p_{FDR} = 0.063$), hence, future studies are needed to confirm this finding. In our previous work investigating disease stage-dependent effects of sTREM2-related microglial activation on p-tau₁₈₁ increases, we found that in patients within earliest Aβ pathology (defined as Aβ CSF positive and amyloid-PET negative) (Palmqvist et al, 2017), sTREM2 mediated Aβ-related p-tau₁₈₁ increases (Biel et al, 2023). In addition, early Aβ pathology was associated with glucose hypermetabolism, indicating that sTREM2 follows earliest Aβ fibrillization, which might manifest in activated microglia consuming more glucose (Xiang et al, 2021). Our current observations align well with findings using TSPO-PET as a proxy of microglial activation, where TSPO-PET was associated with higher tau-PET signals in female but not in male AD patients (Biechele et al, 2024). Similarly, in post-mortem investigations, microglial activation was linked to Aβ-related tau pathology in women but not in men (Casetto et al, 2022). Hence, microglial-induced tau accumulation might be more pronounced in women than in men.




Figure 2. Interaction effects of potential modulators on the association between amyloid-PET (in centiloid) and CSF p-tau₁₈₁ across A β —cognitively normal plus A β + ranging from cognitively normal to AD demented (longitudinal sample: *N* = 322; sTREM2 sample: *N* = 454).

A significant interaction effect was found between centiloid and sex (male: *n* = 156; female: *n* = 166) on cross-sectional (A) and longitudinal (B) p-tau₁₈₁ levels (B only borderline significant after FDR correction). No significant interaction effects were found between centiloid and sTREM2 (C), age (D, E) or ApoE4 status (non-carriers: *n* = 185; carriers: *n* = 137) (F, G) on cross-sectional/longitudinal p-tau₁₈₁ levels. Standardized beta-estimates (β) and *p*-values were derived from linear regressions. (A) and (B) were controlled for age, education, and clinical status; (C), (F), and (G) were controlled for sex, age, education, and clinical status, and (D) and (E) were controlled for sex, education, and clinical status. * = *p*_{FDR} < 0.05; # = *p*_{FDR} < 0.1.

Biologically, women are predisposed to higher levels of neuroinflammatory markers than men, which has been shown using TSPO-PET across studies in healthy adults (Tuisku et al, 2019) and animal models of amyloidosis (Biechele et al, 2020). Preclinical research found that microglia have transcriptional sex differences in adult brains, suspected to be caused by sex chromosomes as well as sex hormones that might be involved in microglial functioning (Guillot-Sestier et al, 2021; Kodama and Gan, 2019; Villa et al, 2018). In addition, women are more often affected by autoimmune diseases of the central nervous system, such as multiple sclerosis (Kalincik et al, 2013; Koch-Henriksen and Sorensen, 2010), which has been further attributed to maladaptive microglial activation (Yong, 2022). Thus, sex-specific differences in microglial activation in women might result in a higher vulnerability to chronic neuroinflammation, which may cause neuronal damage (Bivona et al, 2023; Jayaraman et al, 2021). It would be critical to assess, whether the observed association between sTREM2-related microglial activation and p-tau₁₈₁ is mediated by pro-inflammatory cytokines (e.g., Interleukin 1 β), which might result from prolonged microglial activation as a response to earliest A β fibrillization (Wang et al, 2015). Here, it should be tested, whether the threshold for a pro-inflammatory cytokine response differs between men and women. In addition, future studies should include additional markers related to neuroinflammation in the CSF (e.g., YKL-40, ICAM-1, VCAM1) (Janelidze et al, 2018; Popp et al, 2017) or tissue (e.g., TSPO-PET, FDG-PET) (Xiang et al, 2021) to address the underlying mechanism that link neuroinflammation and p-tau secretion. Moreover, future investigations could benefit from incorporating proteomic analyses to further explore more complex patterns of neuroinflammation markers, particularly those related to microglial activation. Detrimental effects of microglial activation in early disease stages of AD are in contrast to the observed positive effects microglial activation might have in later stages of AD, such as protective effects on A β pathology, neurodegeneration, and cognitive decline (Ewers et al, 2020; Ewers et al, 2019; Morenas-Rodriguez et al, 2022). We therefore suggest to consider subanalyses in clinical trials that are stratified by sex and disease stage, as our findings indicate that men and women show different dynamics in AD disease pathways. These might be driven among others by a different response to microglial activation and presumably earlier thresholds for A β -related neuroinflammation in women than in men.

Besides the association between sTREM2-related microglial activation and p-tau₁₈₁, we observed a main effect of ApoE4 status on cross-sectional p-tau₁₈₁ as well as longitudinal p-tau₁₈₁ increases, which supports our previous work showing that ApoE4 enhances tau spreading using tau-PET (Steward et al, 2023). From a mechanistic point of view, it has been shown that the ApoE4 allele interferes with the absorption of polyunsaturated fatty acids,

which are vital for the cell's functioning. As a consequence of ApoE4, fewer nutrients can be absorbed, the cells become inflamed and ultimately die (Asaro et al, 2020). This inflammatory reaction might promote the secretion of soluble tau, similar to the observed effects of sTREM2-related microglial activation on p-tau (Biel et al, 2023). Indeed, previous work reported that ApoE4 facilitates microglia-related neuroinflammation and thereby might contribute to AD pathways (Kang et al, 2018; Krasemann et al, 2017; Parhizkar and Holtzman, 2022; Tai et al, 2015; Ulrich et al, 2018). Specifically, it was recently shown that ApoE4 activates microglia within brain regions that are prone to early tau propagation, and this effect was independent of A β (Ferrari-Souza et al, 2023). In addition, and in line with previous observations (Altmann et al, 2014; Babapour Mofrad et al, 2020; Damoiseaux et al, 2012; Hohman et al, 2018), we found that female ApoE4 risk allele carriers show higher levels of cross-sectional p-tau₁₈₁ compared to male ApoE4 risk allele carriers. Importantly, higher microglia-induced inflammatory states were previously found in female ApoE4 carriers compared to male ApoE4 carriers (Mhatre-Winters et al, 2022), suggesting similar sex-specific associations between sTREM2- and ApoE4-related neuroinflammation and p-tau₁₈₁ levels. However, with the data of the present study, causal conclusions are limited, thus, future work is needed to test the link between ApoE4-induced cell inflammation and subsequent p-tau secretion. Further, our finding of increased p-tau₁₈₁ in ApoE4 carriers may reflect, in part, their predisposition toward earlier A β pathology onset and thus a more advanced disease stage (Therriault et al, 2021). Given that ApoE4 carriers in our study show higher A β positivity and load (Figs. 1 and 2), the observed association with p-tau₁₈₁ could be influenced by their progression along the amyloid cascade. Future longitudinal studies with stage-specific controls would help clarify whether this relationship is independent of ApoE4's effects on A β progression. In contrast, ApoE4 status did not modulate the association between A β and p-tau₁₈₁, which seems surprising since ApoE4 has been extensively identified as a driver of A β pathology (Liu et al, 2017; Morris et al, 2010; Reiman et al, 2009). Similarly, the interaction between ApoE4 and sex on p-tau₁₈₁ was no longer present when including A β as interaction term. Recently, we found that A β mediates the association between ApoE4 and faster tau accumulation in regions that are vulnerable for early tau aggregation (Steward et al, 2023), thus, ApoE4 might only drive A β -related p-tau increases in early AD disease stages, while in later disease, the effects of ApoE4 on p-tau might be independent of A β fibrillization. Along the same lines, it has been noted that the interaction between ApoE4 and sex on p-tau levels is only persistent in early disease stages (subjective cognitive decline and MCI, but not in dementia) (Babapour Mofrad et al, 2020), consistent with another study reporting an ApoE4 x sex interaction on tau-PET only within early regions of




Figure 3. Sex as modulator for the effects of CSF sTREM2 and ApoE4 carrier status on CSF p-tau₁₈₁ across Aβ⁻ cognitively normal plus Aβ⁺ ranging from cognitively normal to AD demented (ApoE4 sample: *N* = 322; sTREM2 sample: *N* = 454).

Female sex compared to male sex (male: *n* = 244; female: *n* = 210) is associated with a stronger association between sTREM2 and p-tau₁₈₁ levels (A). Stronger association between ApoE4 carrier status (non-carriers: *n* = 185; carriers: *n* = 137) and p-tau₁₈₁ in women than in men (B). 3-way interaction effect of centiloid, sTREM2, and sex on p-tau₁₈₁ levels with women showing a stronger association between centiloid and p-tau₁₈₁ with increasing sTREM2 levels ($\beta = 0.312$, $T = 2.316$, $p = 0.021$, $p_{FDR} = 0.063$) (C). Standardized beta-estimates (β) and *p*-values were derived from linear regressions. (A) and (B) were controlled for age, education, clinical status, and centiloid. (C) was controlled for age, education, and clinical status. The center line of the boxplot (B) indicates the median (50th percentile), the bounds of the box show the interquartile range (25–75th percentiles), and the whiskers extend to 1.5 times the interquartile range from the edges of the box. * = $p_{FDR} < 0.05$.

tau deposition (Wang et al, 2021). In the context of microglial activation and neuroinflammation, we also previously showed that sTREM2 mediates Aβ-related p-tau₁₈₁ increases only in early Aβ fibrillization (Biel et al, 2023). It would be a key next step to test whether the observed sex interactions with sTREM2 and ApoE4 on

p-tau₁₈₁ are disease stage-dependent and whether they are related to each other.

Finally, we did not observe any effects of age on cross-sectional or longitudinal p-tau₁₈₁ levels, neither a main effect nor an interaction with Aβ or sex. Older age is the major risk factor for developing AD (Guerreiro and Bras, 2015; Hou et al, 2019). However, younger age at symptom onset has been conversely found to be associated with accelerated tau accumulation (Smith et al, 2020), neurodegeneration (Moller et al, 2013), cognitive decline (van der Vlies et al, 2009) and higher rates of mortality in AD (Koedam et al, 2008). Therefore, we tested whether accelerated spread of tau in younger patients can be further explained by a stronger association between Aβ and p-tau₁₈₁, which was not confirmed by our analyses. Therefore, faster tau accumulation in younger AD patients is unlikely driven by a higher Aβ-related p-tau response and it is unclear why tau accumulates in younger patients at a faster rate and whether female patients with an early onset show a faster spreading of tau. Here, future research should further address the underlying mechanisms of tau accumulation in patients with an earlier disease onset.

A strength of this study is the inclusion of several biomarker assessments in relation to sex differences in AD, investigating modulating effects on the Aβ to p-tau axis within a large sample ranging from cognitively normal to demented. However, several limitations should be addressed when interpreting our data. First, sTREM2 data have been obtained relatively late in the ADNI dataset, hence, data with subsequent CSF p-tau₁₈₁ for assessing longitudinal relationships were limited. Since we previously show that sTREM2 mediated the association between Aβ and p-tau₁₈₁ only in earliest Aβ fibrillization, we restricted the analysis on cross-sectional data for the sTREM2 sample in order to increase the sample covering Aβ⁻ controls to Aβ⁺ patients across the AD spectrum to 454 participants. We encourage future studies to assess sex differences in longitudinal associations between Aβ, sTREM2, and p-tau₁₈₁ once more data are available. Second, sTREM2 is only an indirect marker of microglial activation, thus other direct (e.g., post-mortem) or indirect (e.g., TSPO-PET) marker should be included in future studies. Third, in the present study, not sufficient tau-PET data were available to reliably test whether the stronger p-tau₁₈₁ response in women promotes faster spreading of tau aggregates. Once more data are available, this might be an important target for future investigations. Finally, the analysis should be replicated in other cohorts than ADNI and include more diverse participant groups with different ethnicities in order to increase generalizability of our findings.

In conclusion, our findings show that sex is an important modulator of Aβ-dependent p-tau₁₈₁ secretion. In particular, women show a stronger association between sTREM2-related microglial activation and p-tau₁₈₁ than men, supporting the view that neuroinflammation may play a key role in the observed sex differences in AD. In addition, we found higher p-tau₁₈₁ levels in female ApoE4 carriers compared to male ApoE4 carriers, which might be as well attributable to greater neuroinflammatory effects of ApoE4 in women. Our study provides evidence for sex-specific dynamics of AD disease pathways related to neuroinflammation and has potential implications for drug treatments targeting microglial activation, in which sex should be considered as an important modulating factor.

Methods

Reagents and tools table

Reagent/Resource	Reference or Source	Identifier or Catalog Number
Experimental models		
Alzheimer's disease cohort sample	Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu)	Phase ADNI2, ADNI3, ADNIGO
Recombinant DNA		
Not applicable		
Antibodies		
Biotinylated polyclonal goat anti-human TREM2 antibody	R&D Systems BAF1828	Suarez-Calvet et al (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8:466-476
Monoclonal mouse anti-human TREM2 antibody	Santa Cruz Biotechnology; B-3, sc373828	
SULFO-TAG-labeled anti-mouse secondary antibody	Meso Scale Discovery	
Oligonucleotides and other sequence-based reagents		
Not applicable		
Chemicals, Enzymes and other reagents		
Not applicable		
Software		
R statistical software version 4.0.2	http://www.R-project.org/ ;	
Statistical analysis: lmer, aov, lm.beta, lm	R Core Team, 2021. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.	
Visualization: ggplot		
Other		

Participants

To determine the effects of sex, age, and ApoE4 on cross-sectional and longitudinal p-tau₁₈₁ levels, we included 322 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with availability of ¹⁸F-florbetapir/¹⁸F-florbetaben amyloid-PET, ApoE4 status, demographical information (sex, age, education), clinical status as well as longitudinal p-tau₁₈₁ data (>1 measurement). Baseline data had to be obtained within a time window of 6 months for participants to be included in this study. Participants were classified as ApoE4 risk allele carriers when at least one ε4 allele was present. For specifically assessing the effects of sTREM2, we included a larger sample of 454 ADNI participants with CSF sTREM2 in addition to available ¹⁸F-florbetapir/¹⁸F-florbetaben amyloid-PET, demographical information (sex, age, education), and clinical status. Only cross-sectional p-tau₁₈₁ data were included for the sTREM2 sample since longitudinal p-tau₁₈₁ was not sufficiently available to specifically assess effects of sTREM2-related microglial activation on p-tau₁₈₁ change rates. Clinical status was defined by ADNI investigators as cognitively normal (CN; Mini Mental State Examination [MMSE] ≥ 24, Clinical Dementia Rating [CDR] = 0, non-depressed), mild cognitive impairment (MCI; MMSE ≥ 24, CDR = 0.5, objective memory-impairment on education-adjusted Wechsler Memory Scale II, preserved activities of daily living) or dementia (MMSE = 20–26, CDR ≥ 0.5, NINCDS/ADRDA criteria for probable AD). Aβ status (–/+) was determined using tracer-specific cut-offs for global amyloid-PET (i.e., Aβ+ = SUVR > 1.11/1.08 for ¹⁸F-florbetapir (Landau et al, 2012)/¹⁸F-florbetaben (Royse et al, 2021)). The study is in accordance with the Declaration of Helsinki. Ethical approval was obtained by ADNI investigators, and all study participants provided written informed consent.

CSF acquisition

The ADNI biomarker core team at the University of Pennsylvania assessed CSF p-tau₁₈₁ data using an electrochemiluminescence immunoassays Elecsys on a fully automated Elecsys cobas e 601

Table 3. Effects of sex for the association between potential modulators and cross-sectional/longitudinal CSF p-tau₁₈₁ and between potential modulators and Aβ-related cross-sectional/longitudinal p-tau₁₈₁ levels.

Model	Covariates	Cross-sectional			Longitudinal		
		β	T	p	β	T	p
Interactions modulators x sex on p-tau							
CSF p-tau ₁₈₁ ~ CSF sTREM2*sex	Age, education, clinical status, CL	0.179	2.177	0.030*			
CSF p-tau ₁₈₁ ~ age*sex	Education, clinical status, CL	−0.542	−1.005	0.315	−0.442	−0.735	0.463
CSF p-tau ₁₈₁ ~ ApoE4*sex	Age, education, clinical status, CL	0.173	2.185	0.030*	0.100	1.119	0.264
Interactions CL x modulators x sex on p-tau							
CSF p-tau ₁₈₁ ~ CL*sTREM2*sex	Age, education, clinical status	0.312	2.316	0.021#			
CSF p-tau ₁₈₁ ~ CL*age*sex	Education, clinical status	0.008	0.009	0.993	0.352	0.357	0.721
CSF p-tau ₁₈₁ ~ CL*ApoE4*sex	Age, education, clinical status	0.051	0.362	0.718	0.075	0.476	0.634

Interaction effects between potential modulators and sex on p-tau₁₈₁ as well as interaction effects between amyloid-PET (in centiloid; CL), potential modulators, and sex on p-tau₁₈₁ levels were calculated using linear regressions. * = p_{FDR} < 0.05; # = p_{FDR} < 0.1.

instrument and a single lot of reagents for each biomarker. sTREM2 data were assessed using a previously described ELISA approach using the MSD Platform (Ewers et al, 2019; Kleinberger et al, 2014; Suarez-Calvet et al, 2016) and are provided in the ADNIHAASSWASHULAB.csv file on the ADNI database (variable “MSDSTREM2CORRECTED”). For a detailed description of the applied methods, see <https://ida.loni.usc.edu>.

MRI and PET acquisition and preprocessing

ADNI acquired 3T structural MRI of T1-weighted MPRAGE sequences using unified scanning protocols (<http://adni.loni.usc.edu/methods/mri-tool/mri-analysis/>). Amyloid-PET was recorded 50–70 min after ^{18}F -florbetapir injection in 4×5 min frames or 90–110 min after ^{18}F -florbetaben injection in 4×5 min frames. The recorded time frames were motion corrected and averaged to obtain mean images (<http://adni.loni.usc.edu/methods/pet-analysis-method/pet-analysis/>). Next, the Advanced Normalization Tools (ANTs (Avants et al, 2011)) high-dimensional warping algorithm was used to estimate nonlinear spatial normalization parameters based on structural skull-stripped T1-weighted images. After amyloid-PET images were co-registered to native-space T1-weighted images, the ANTs-derived normalization parameters were used to normalize the images to Montreal Neurological Institute (MNI) space. Amyloid-PET SUVRs were intensity normalized to the whole cerebellum. Global amyloid-PET SUVRs were transformed to the centiloid scale in order to harmonize between ^{18}F -florbetapir and ^{18}F -florbetaben A β tracers (Klunk et al, 2015).

Statistical analyses

All statistical analyses were performed using R statistical software version 4.0.2 (<http://www.R-project.org>) (R Core Team, 2021).

Baseline characteristics between controls (i.e., CN A β –) and A β – were compared using ANOVAs for continuous and chi-squared tests for categorical data. Except for the CSF sTREM2 analysis where only cross-sectional data were available, all analyses were performed both on cross-sectional and longitudinal CSF p-tau₁₈₁. Longitudinal p-tau₁₈₁ was determined as the annual rate of change in p-tau₁₈₁ using a linear mixed model with time from baseline as the independent variable, incorporating random intercepts and slopes to account for individual variability, with a covariance term between the random intercept and slope for each individual (Biel et al, 2023; Pichet Binette et al, 2022; Preische et al, 2019).

First, we tested the main effects of potential A β to p-tau modulators on cross-sectional and longitudinal p-tau₁₈₁ levels. We calculated ANCOVAs for nominal potential modulators (i.e., sex, ApoE4) and linear regressions for metric potential modulators (i.e., sTREM2, age). Potential A β to p-tau modulators were included as independent variables and cross-sectional or longitudinal p-tau₁₈₁ as dependent variable. The models were controlled for sex, age, education, clinical status, and amyloid-PET (i.e., centiloid), whereby sex and age were not included as covariates in the models testing sex or age as independent variable, respectively. For our main analysis, we aimed to investigate modulating effects of sex, sTREM2, age, and ApoE4 on the association between centiloid and p-tau₁₈₁. To that end, we ran separate linear regressions, including centiloid and potential modulators as independent variables and cross-sectional or longitudinal p-tau₁₈₁ as

The paper explained

Problem

In Alzheimer's disease (AD), the accumulation of A β pathology triggers the secretion of phosphorylated tau (p-tau) from neurons which drives the aggregation and spread of fibrillar tau pathology ensuing neurodegeneration and cognitive decline. Therefore, A β -related increases in p-tau are a critical event in the amyloid cascade triggering the progression of AD. Thus, it is of particular importance to characterize potential modulators of A β -related p-tau increases which may alter downstream tau aggregation and spread. Previous studies have linked female sex, microglial activation, younger age, and the genetic risk factor ApoE4 to altered tau levels in AD. Thus, we systematically tested whether these factors modulate the association between baseline levels of PET-assessed A β pathology and cross-sectional or longitudinal p-tau increases in the CSF.

Results

We found that higher amyloid-PET was linked to elevated p-tau where only female sex compared to male sex was associated with higher A β -related p-tau levels (i.e., interaction between amyloid-PET and sex). In contrast, higher sTREM2 levels and ApoE4 positivity were related to constitutively elevated p-tau across the low to high A β spectrum (i.e., main effect), while there was no effect of sex or age. However, sex further modulated the observed main effects, with higher sTREM2-related p-tau levels in women compared to men and a stronger effect in female ApoE4 risk allele carriers on p-tau levels compared to their male counterparts.

Impact

Together, our results show that ApoE4 and sTREM2 are associated with higher p-tau levels, with stronger effects in women. Of factors known to modulate tau pathology in AD, sex alone modulated the A β to p-tau axis, where female sex is associated with a stronger A β -dependent p-tau secretion, potentially driven by elevated sTREM2-related microglial activation. These findings help to understand heterogeneous disease progression in men and women which might be critical for clinical trials, especially for drug treatments targeting microglial activation as a disease modifying approach.

dependent variable. Covariates of the models were sex, age, education, and clinical status, whereby sex and age were not included in the models testing sex or age as independent variable, respectively. Please refer to Table 2 for a depiction of the statistical equations used within each model.

To further assess whether effects differ between men and women, we repeated the analyses for the main and interaction effects adding sex as interaction term. First, we assessed modulator (i.e., sTREM2, age, ApoE4) $\times$ sex interactions on cross-sectional or longitudinal p-tau₁₈₁, including potential modulators and sex as independent and cross-sectional or longitudinal p-tau₁₈₁ as dependent variable. The models were controlled for age, education, clinical status, and centiloid. Next, we examined 3-way interactions of centiloid, potential modulators, and sex on cross-sectional or longitudinal p-tau₁₈₁. Here, we included centiloid, potential modulators, and sex as independent variables and cross-sectional or longitudinal p-tau₁₈₁ as dependent variable. The models were controlled for age, education, and clinical status. Age was not included in the model testing age as independent variable. Please refer to Table 3 for a depiction of the statistical equations used within each analysis.

To assess effect sizes for significant results, partial R^2 values were calculated for linear models and partial eta-squared (η^2) for ANCOVAs.

Each of our four analyses (i.e., main effects, CL x modulator, modulator x sex, CL x modulator x sex) was corrected for multiple comparisons for cross-sectional and longitudinal measurements separately using the false discovery rate (FDR) approach within the p.adjust R function.

Data availability

All data used in this manuscript are publicly available from the ADNI database (adni.loni.usc.edu) upon registration and compliance with the data use agreement. The data that support the findings of this study are available upon reasonable request from the corresponding author.

The source data of this paper are collected in the following database record: [biostudies:S-SCDT-10_1038-S44321-024-00190-3](https://biostudies.nlm.nih.gov/study/10.1038/S44321-024-00190-3).

Peer review information

A peer review file is available at <https://doi.org/10.1038/s44321-024-00190-3>

References

- Altmann A, Tian L, Henderson VW, Greicius MD, Alzheimer's Disease Neuroimaging Initiative I (2014) Sex modifies the APOE-related risk of developing Alzheimer disease. *Ann Neurol* 75:563–573
- Alzheimer's A (2014) 2014 Alzheimer's disease facts and figures. *Alzheimers Dement* 10:e47–92
- Asaro A, Carlo-Spiewok AS, Malik AR, Rothe M, Schipke CG, Peters O, Heeren J, Willnow TE (2020) Apolipoprotein E4 disrupts the neuroprotective action of sortilin in neuronal lipid metabolism and endocannabinoid signaling. *Alzheimers Dement* 16:1248–1258
- Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC (2011) A reproducible evaluation of ANTs similarity metric performance in brain image registration. *Neuroimage* 54:2033–2044
- Babapour Mofrad R, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Sikkes SAM, Teunissen CE (2020) Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE epsilon4 genotype. *Neurology* 95:e2378–e2388
- Bianchi VE (2019) The anti-inflammatory effects of testosterone. *J Endocr Soc* 3:91–107
- Biechele G, Franzmeier N, Blume T, Ewers M, Luque JM, Eckenweber F, Sacher C, Beyer L, Ruch-Rubinstein F, Lindner S et al (2020) Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases. *J Neuroinflammation* 17:374
- Biechele G, Rauchmann BS, Janowitz D, Buerger K, Franzmeier N, Weidinger E, Guersel S, Schuster S, Finze A, Harris S et al (2024) Associations between sex, body mass index and the individual microglial response in Alzheimer's disease. *J Neuroinflammation* 21:30
- Biel D, Suarez-Calvet M, Hager P, Rubinski A, Dewenter A, Steward A, Roemer S, Ewers M, Haass C, Brendel M et al (2023) sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer's disease. *EMBO Mol Med* 15:e16987
- Bivona G, Iemmolo M, Agnello L, Lo Sasso B, Gambino CM, Giglio RV, Scazzone C, Ghersi G, Ciaccio M (2023) Microglial activation and priming in Alzheimer's disease: state of the art and future perspectives. *Int J Mol Sci* 24:884
- Blanchard JW, Akay LA, Davila-Velderrain J, von Maydell D, Mathys H, Davidson SM, Effenberger A, Chen CY, Maner-Smith K, Hajjar I et al (2022) APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. *Nature* 611:769–779
- Brelstaff JH, Mason M, Katsinelos T, McEwan WA, Ghatti B, Tolkskovsky AM, Spillantini MG (2021) Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates. *Sci Adv* 7:eabg4980
- Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T, Albert NL, Carlsen J, Lindner S, Gildehaus FJ et al (2017) Increase of TREM2 during aging of an Alzheimer's disease mouse model is paralleled by microglial activation and amyloidosis. *Front Aging Neurosci* 9:8
- Buckley RF, Mormino EC, Chhatwal J, Schultz AP, Rabin JS, Rentz DM, Acar D, Properzi MJ, Dumurgier J, Jacobs H et al (2019a) Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. *Neurobiol Aging* 78:178–185
- Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, Jacobs HIL, Papp KV, Amariglio RE, Properzi MJ et al (2019b) Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. *JAMA Neurol* 76:542–551
- Casaleto KB, Nichols E, Aslanyan V, Simone SM, Rabin JS, LaJoie R, Brickman AM, Dams-O'Connor K, Palta P, Kumar RG et al (2022) Sex-specific effects of microglial activation on Alzheimer's disease proteinopathy in older adults. *Brain* 145(10):3536–3545
- Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, Rosen HJ, Miller BL, Kramer JH, Greicius MD, Alzheimer's Disease Neuroimaging I (2012) Gender modulates the APOE epsilon4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. *J Neurosci* 32:8254–8262
- Dujardin S, Commins C, Lathuilliere A, Beerepoot P, Fernandes AR, Kamath TV, De Los Santos MB, Klickstein N, Corjuc DL, Corjuc BT et al (2020) Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. *Nat Med* 26:1256–1263
- Ewers M, Biechele G, Suarez-Calvet M, Sacher C, Blume T, Morenas-Rodriguez E, Deming Y, Piccio L, Cruchaga C, Kleinberger G et al (2020) Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. *EMBO Mol Med* 12:e12308
- Ewers M, Franzmeier N, Suarez-Calvet M, Morenas-Rodriguez E, Caballero MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M et al (2019) Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. *Sci Transl Med* 11:eaav6221
- Ferrari-Souza JP, Lussier FZ, Leffa DT, Theriault J, Tissot C, Bellaver B, Ferreira PCL, Malpetti M, Wang YT, Povola G et al (2023) APOEepsilon4 associates with microglial activation independently of Abeta plaques and tau tangles. *Sci Adv* 9:eade1474
- Fisher DW, Bennett DA, Dong H (2018) Sexual dimorphism in predisposition to Alzheimer's disease. *Neurobiol Aging* 70:308–324
- Franzmeier N, Suarez-Calvet M, Frontzkowski L, Moore A, Hohman TJ, Morenas-Rodriguez E, Nuscher B, Shaw L, Trojanowski JQ, Dichgans M et al (2020) Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. *Mol Neurodegener* 15:57
- Frontzkowski L, Ewers M, Brendel M, Biel D, Ossenkoppele R, Hager P, Steward A, Dewenter A, Römer S, Rubinski A et al (2022) Earlier Alzheimer's disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading. *Nat Commun* 13:4899

- Glenner GG, Wong CW (1984) Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. *Biochem Biophys Res Commun* 122:1131-1135
- Guerreiro R, Bras J (2015) The age factor in Alzheimer's disease. *Genome Med* 7:106
- Guillot-Sestier MV, Araiz AR, Mela V, Gaban AS, O'Neill E, Joshi L, Chouchani ET, Mills EL, Lynch MA (2021) Microglial metabolism is a pivotal factor in sexual dimorphism in Alzheimer's disease. *Commun Biol* 4:711
- Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297:353-356
- Hogervorst E, Lehmann DJ, Warden DR, McBroom J, Smith AD (2002) Apolipoprotein E epsilon4 and testosterone interact in the risk of Alzheimer's disease in men. *Int J Geriatr Psychiatry* 17:938-940
- Hohman TJ, Dumitrescu L, Barnes LL, Thambisetty M, Beecham G, Kunkle B, Gifford KA, Bush WS, Chibnik LB, Mukherjee S et al (2018) Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. *JAMA Neurol* 75:989-998
- Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA (2019) Ageing as a risk factor for neurodegenerative disease. *Nat Rev Neurol* 15:565-581
- Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J et al (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's Dement* 14:535-562
- Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K, Hansson O (2018) CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. *Neurology* 91:e867-e877
- Jayaraman A, Htike TT, James R, Picon C, Reynolds R (2021) TNF-mediated neuroinflammation is linked to neuronal necroptosis in Alzheimer's disease hippocampus. *Acta Neuropathol Commun* 9:159
- Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. *Proc Natl Acad Sci USA* 108:5819-5824
- Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C et al (2013) Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. *Brain* 136:3609-3617
- Kang SS, Ebbert MTW, Baker KE, Cook C, Wang X, Sens JP, Kocher JP, Petrucelli L, Fryer JD (2018) Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. *J Exp Med* 215:2235-2245
- Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B et al (2017) A unique microglia type associated with restricting development of Alzheimer's disease. *Cell* 169:1276-1290.e1217
- Kilby EL, Kelly DM, Jones TH (2021) Testosterone stimulates cholesterol clearance from human macrophages by activating LXRalpha. *Life Sci* 269:119040
- Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F et al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. *Sci Transl Med* 6:243ra286
- Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Sr MD, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ et al (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement* 11:1-15.e11-14
- Koch-Henriksen N, Sorensen PS (2010) The changing demographic pattern of multiple sclerosis epidemiology. *Lancet Neurol* 9:520-532
- Kodama L, Gan L (2019) Do microglial sex differences contribute to sex differences in neurodegenerative diseases? *Trends Mol Med* 25:741-749
- Koedam EL, Pijnenburg YA, Deeg DJ, Baak MM, van der Vlies AE, Scheltens P, van der Flier WM (2008) Early-onset dementia is associated with higher mortality. *Dement Geriatr Cogn Disord* 26:147-152
- Komarova NL, Thalhauser CJ (2011) High degree of heterogeneity in Alzheimer's disease progression patterns. *PLoS Comput Biol* 7:e1002251
- Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z et al (2017) The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. *Immunity* 47:566-581.e569
- Landau SM, Lee JQ, Murphy A, Ward TJ, Harrison TM, Baker SL, Jagust WJ (2022) Tau heterogeneity in Aβ positive patients. *Alzheimer's Dement* 18:e063765
- Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ, Alzheimer's Disease Neuroimaging I (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Ann Neurol* 72:578-586
- Laws KR, Irvine K, Gale TM (2018) Sex differences in Alzheimer's disease. *Curr Opin Psychiatry* 31:133-139
- Lee SI, Jeong W, Lim H, Cho S, Lee H, Jang Y, Cho J, Bae S, Lin YT, Tsai LH et al (2021) APOE4-carrying human astrocytes oversupply cholesterol to promote neuronal lipid raft expansion and Aβ generation. *Stem Cell Rep* 16:2128-2137
- Levine DA, Gross AL, Briceno EM, Tilton N, Giordani BJ, Sussman JB, Hayward RA, Burke JF, Hingtgen S, Elkind MSV et al (2021) Sex differences in cognitive decline among US adults. *JAMA Netw Open* 4:e210169
- Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, Bu G (2017) ApoE4 accelerates early seeding of amyloid pathology. *Neuron* 96:1024-1032.e1023
- Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, Lamb BT, Bhaskar K (2015) Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. *Brain* 138:1738-1755
- Mhatre-Winters I, Eid A, Han Y, Tieu K, Richardson JR (2022) Sex and APOE genotype alter the basal and induced inflammatory states of primary microglia from APOE targeted replacement mice. *Int J Mol Sci* 23:9829
- Moller C, Vrenken H, Jiskoot L, Versteeg A, Barkhof F, Scheltens P, van der Flier WM (2013) Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. *Neurobiol Aging* 34:2014-2022
- Morenas-Rodriguez E, Li Y, Nuscher B, Franzmeier N, Xiong C, Suarez-Calvet M, Fagan AM, Schultz S, Gordon BA, Benzinger TLS et al (2022) Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. *Lancet Neurol* 21:329-341
- Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann Neurol* 67:122-131
- Mosconi L, Berti V, Quinn C, McHugh P, Petrongolo G, Varsavsky I, Osorio RS, Pupi A, Vallabhajosula S, Isaacson RS et al (2017) Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. *Neurology* 89:1382-1390
- Nebel RA, Aggarwal NT, Barnes LL, Gallagher A, Goldstein JM, Kantarci K, Mallampalli MP, Mormino EC, Scott L, Yu WH et al (2018) Understanding the impact of sex and gender in Alzheimer's disease: a call to action. *Alzheimers Dement* 14:1171-1183
- Ophir G, Amariglio N, Jacob-Hirsch J, Elkon R, Rechavi G, Michaelson DM (2005) Apolipoprotein E4 enhances brain inflammation by modulation of the NF-kappaB signaling cascade. *Neurobiol Dis* 20:709-718
- Ota H, Akishita M, Akiyoshi T, Kahyo T, Setou M, Ogawa S, Iijima K, Eto M, Ouchi Y (2012) Testosterone deficiency accelerates neuronal and vascular aging of SAMP8 mice: protective role of eNOS and SIRT1. *PLoS ONE* 7:e29598

- Palmqvist S, Scholl M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O (2017) Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. *Nat Commun* 8:1214
- Parhizkar S, Holtzman DM (2022) APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease. *Semin Immunol* 59:101594
- Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Theriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK et al (2021) Microglial activation and tau propagate jointly across Braak stages. *Nat Med* 27:1592-1599
- Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D, Alzheimer's Disease Neuroimaging I, Strandberg O, Janelidze S, Palmqvist S et al (2022) Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease. *Nat Commun* 13:6635
- Popp J, Oikonomidi A, Tautvydaite D, Dayon L, Bacher M, Migliavacca E, Henry H, Kirkland R, Severin I, Wojcik J, Bowman GL (2017) Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. *Brain Behav Immun* 62:203-211
- Preisiche O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Graber S, Kuder-Buletta E, LaFougere C, Laske C et al (2019) Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. *Nat Med* 25:277-283
- R Core Team (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
- Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB et al (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. *Proc Natl Acad Sci USA* 106:6820-6825
- Royse SK, Minhas DS, Lopresti BJ, Murphy A, Ward T, Koeppe RA, Bullich S, DeSanti S, Jagust WJ, Landau SM, Alzheimer's Disease Neuroimaging I (2021) Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. *Alzheimers Res Ther* 13:99
- Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med* 8:595-608
- Shi Y, Yamada K, Liddel SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC et al (2017) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature* 549:523-527
- Shokouhi S, Taylor WD, Albert K, Kang H, Newhouse PA, Alzheimer's Disease Neuroimaging I (2020) In vivo network models identify sex differences in the spread of tau pathology across the brain. *Alzheimers Dement* 12:e12016
- Smith R, Strandberg O, Mattsson-Carlsson N, Leuzy A, Palmqvist S, Pontecorvo MJ, Devous MD, Ossenkoppele R, Hansson O (2020) The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. *Brain* 143:3805-3815
- Steward A, Biel D, Dewenter A, Roemer S, Wagner F, Dehsarvi A, Rathore S, Otero Svaldi D, Higgins I, Brendel M et al (2023) ApoE4 and connectivity-mediated spreading of tau pathology at lower amyloid levels. *JAMA Neurol* 80:1295-1306
- Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD et al (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. *EMBO Mol Med* 8:466-476
- Suarez-Calvet M, Morenas-Rodriguez E, Kleinberger G, Schlepckow K, Araque Caballero MA, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E et al (2019) Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-beta pathology. *Mol Neurodegener* 14:1
- Sundermann EE, Panizzon MS, Chen X, Andrews M, Galasko D, Banks SJ, Alzheimer's Disease Neuroimaging I (2020) Sex differences in Alzheimer's-related Tau biomarkers and a mediating effect of testosterone. *Biol Sex Differ* 11:33
- Tai LM, Ghura S, Koster KP, Liakaitis V, Maienschein-Cline M, Kanabar P, Collins N, Ben-Aissa M, Lei AZ, Bahroos N et al (2015) APOE-modulated Abeta-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. *J Neurochem* 133:465-488
- Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, Thomas E, Kang MS, Lussier F, Tissot C et al (2021) APOEepsilon4 potentiates the relationship between amyloid-beta and tau pathologies. *Mol Psychiatry* 26:5977-5988
- Touroutoglou A, Katsumi Y, Brickhouse M, Zaitsev A, Eckbo R, Aisen P, Beckett L, Dage JL, Eloyan A, Foroud T et al (2023) The sporadic early-onset Alzheimer's disease signature of atrophy: preliminary findings from the longitudinal early-onset Alzheimer's disease study (LEADS) cohort. *Alzheimers Dement* 19(Suppl 9):S74-S88
- Tsisknia AA, Edland SD, Sundermann EE, Reas ET, Brewer JB, Galasko D, Banks SJ, Alzheimer's Disease Neuroimaging I (2022) Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression. *Mol Psychiatry* 27:4314-4322
- Tuisku J, Plaven-Sigra P, Gaiser EC, Airas L, Al-Abdulrasul H, Bruck A, Carson RE, Chen MK, Cosgrove KP, Ekblad L et al (2019) Effects of age, BMI and sex on the glial cell marker TSPO—a multicentre ^{11}C PBR28 HRRT PET study. *Eur J Nucl Med Mol Imaging* 46:2329-2338
- Ulrich JD, Ulland TK, Mahan TE, Nystrom S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H et al (2018) ApoE facilitates the microglial response to amyloid plaque pathology. *J Exp Med* 215:1047-1058
- van der Vlies AE, Koedam EL, Pijnenburg YA, Twisk JW, Scheltens P, van der Flier WM (2009) Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset. *Psychol Med* 39:1907-1911
- Vest RS, Pike CJ (2013) Gender, sex steroid hormones, and Alzheimer's disease. *Horm Behav* 63:301-307
- Villa A, Gelosa P, Castiglioni L, Cimino M, Rizzi N, Pepe G, Lolli F, Marcello E, Sironi L, Vegeto E, Maggi A (2018) Sex-specific features of microglia from adult mice. *Cell Rep* 23:3501-3511
- Vogels T, Murgoci AN, Hromadka T (2019) Intersection of pathological tau and microglia at the synapse. *Acta Neuropathol Commun* 7:109
- Wang WY, Tan MS, Yu JT, Tan L (2015) Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. *Ann Transl Med* 3:136
- Wang YT, Pascoal TA, Theriault J, Kang MS, Benedet AL, Savard M, Tissot C, Lussier FZ, Arias JF, Mathotaarachchi S et al (2021) Interactive rather than independent effect of APOE and sex potentiates tau deposition in women. *Brain Commun* 3:fcab126
- Wang YT, Theriault J, Servaes S, Tissot C, Rahmouni N, Macedo AC, Fernandez-Arias J, Mathotaarachchi SS, Benedet AL, Stevenson J et al (2024) Sex-specific modulation of amyloid-beta on tau phosphorylation underlies faster tangle accumulation in females. *Brain* 147:1497-1510
- Xiang X, Wind K, Wiedemann T, Blume T, Shi Y, Briel N, Beyer L, Biechele G, Eckenweber F, Zatcepin A et al (2021) Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. *Sci Transl Med* 13:eabe5640
- Yong VW (2022) Microglia in multiple sclerosis: protectors turn destroyers. *Neuron* 110:3534-3548

Acknowledgements

Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such,

the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/howtoapply/ADNIAcknowledgementList.pdf>. We thank the ADNI participants and their families who made this study possible. The study was funded by grants from the LMU (FöFoLe, 1119, awarded to DB), the Hertie foundation for clinical neurosciences (awarded to NF), and the SyNergy excellence cluster (EXC 2145/ID 390857198).

Author contributions

Davina Biel: Conceptualization; Data curation; Formal analysis; Investigation; Writing—original draft; Writing—review and editing. **Marc Suárez-Calvet:** Writing—review and editing. **Anna Dewenter:** Writing—review and editing. **Anna Steward:** Writing—review and editing. **Sebastian N Roemer:** Writing—review and editing. **Amir Dehsarvi:** Writing—review and editing. **Zeyu Zhu:** Writing—review and editing. **Julia Pescoller:** Writing—review and editing. **Lukas Frontzkowski:** Writing—review and editing. **Annika Kreuzer:** Writing—review and editing. **Christian Haass:** Data curation; Writing—review and editing. **Michael Schöll:** Writing—review and editing. **Matthias Brendel:** Conceptualization; Writing—review and editing. **Nicolai Franzmeier:** Conceptualization; Data curation; Formal analysis; Investigation; Writing—original draft; Writing—review and editing.

Source data underlying figure panels in this paper may have individual authorship assigned. Where available, figure panel/source data authorship is listed in the following database record: [biostudies:S-SCDT-10_1038-S44321-024-00190-3](https://www.ebi.ac.uk/biostudies/studies/S-SCDT-10_1038-S44321-024-00190-3).

Funding

Open Access funding enabled and organized by Projekt DEAL.

Disclosure and competing interests statement

The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. Creative Commons Public Domain Dedication waiver <http://creativecommons.org/public-domain/zero/1.0/> applies to the data associated with this article, unless otherwise stated in a credit line to the data, but does not extend to the graphical or creative elements of illustrations, charts, or figures. This waiver removes legal barriers to the re-use and mining of research data. According to standard scholarly practice, it is recommended to provide appropriate citation and attribution whenever technically possible.

© The Author(s) 2025